title: Antibody-mediated delivery of therapeutics for cancer therapy.
abstract: BACKGROUND
  Antibody-conjugated therapies (ACTs) combine the specificity of monoclonal antibodies to target cancer cells directly with highly potent payloads, often resulting in superior efficacy and/or reduced toxicity. This represents a new approach to the treatment of cancer. There have been highly promising clinical trial results using this approach with improvements in linker and payload technology. The breadth of current trials examining ACTs in haematological malignancies and solid tumours indicate the potential for clinical impact.
  
  
  METHODS
  This review will provide an overview of ACTs currently in clinical development as well as the principles of antibody delivery and types of payloads used, including cytotoxic drugs, radiolabelled isotopes, nanoparticle-based siRNA particles and immunotoxins.
  
  
  CONCLUSIONS
  The focus of much of the clinical activity in ACTs has, understandably, been on their use as a monotherapy or in combination with standard of care drugs. This will continue, as will the search for better targets, linkers and payloads. Increasingly, as these drugs enter routine clinical care, important questions will arise regarding how to optimise ACT treatment approaches, including investigation of resistance mechanisms, biomarker and patient selection strategies, understanding of the unique toxicities of these drugs, and combinatorial approaches with standard therapies as well as emerging therapeutic agents like immunotherapy.
authors.affiliation: a Tumour Targeting Laboratory , Olivia Newton-John Cancer Research Institute , Melbourne , Australia.|b Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre , Austin Health , Heidelberg, Melbourne , Australia.|c School of Cancer Medicine , La Trobe University , Melbourne , Australia.
authors.forename: Sagun
authors.initials: S
authors.lastname: Parakh
authors.affiliation: a Tumour Targeting Laboratory , Olivia Newton-John Cancer Research Institute , Melbourne , Australia.|c School of Cancer Medicine , La Trobe University , Melbourne , Australia.
authors.forename: Adam C
authors.initials: AC
authors.lastname: Parslow
authors.affiliation: a Tumour Targeting Laboratory , Olivia Newton-John Cancer Research Institute , Melbourne , Australia.|b Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre , Austin Health , Heidelberg, Melbourne , Australia.|c School of Cancer Medicine , La Trobe University , Melbourne , Australia.
authors.forename: Hui K
authors.initials: HK
authors.lastname: Gan
authors.affiliation: a Tumour Targeting Laboratory , Olivia Newton-John Cancer Research Institute , Melbourne , Australia.|c School of Cancer Medicine , La Trobe University , Melbourne , Australia.|d Departmentof Molecular Imaging and Therapy , Austin Health , Melbourne , Australia.|e Department of Medicine , University of Melbourne , Melbourne , Australia.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Scott
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000922:Immunotoxins / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000922:Immunotoxins
keywords: Antibody-conjugated therapies; immunotoxins; radioimmunotherapy; siRNA